Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.

Hu C, Yu M, Ren Y, Li K, Maggio DM, Mei C, Ye L, Wei J, Jin J, Zhuang Z, Tong H.

Sci Rep. 2017 Jun 6;7(1):2894. doi: 10.1038/s41598-017-03058-4.

2.

Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia.

Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M, Burke MH, Ozer HG, Yilmaz SA, Zitzer N, Behbehani GK, Oakes CC, Steiner DJ, Marcucci G, Powell BL, Kolitz JE, Carter TH, Wang ES, Mrózek K, Croce CM, Caligiuri MA, Bloomfield CD, Garzon R, Dorrance AM.

Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4641-E4647. doi: 10.1073/pnas.1703142114. Epub 2017 May 22.

PMID:
28533390
3.

A 3-miRNA signature predicts prognosis of pediatric and adolescent cytogenetically normal acute myeloid leukemia.

Zhu R, Zhao W, Fan F, Tang L, Liu J, Luo T, Deng J, Hu Y.

Oncotarget. 2017 Jun 13;8(24):38902-38913. doi: 10.18632/oncotarget.17151.

4.

MicroRNA-1301 inhibits proliferation of human glioma cells by directly targeting N-Ras.

Zhi T, Jiang K, Zhang C, Xu X, Wu W, Nie E, Yu T, Zhou X, Bao Z, Jin X, Zhang J, Wang Y, Liu N.

Am J Cancer Res. 2017 Apr 1;7(4):982-998. eCollection 2017.

5.

Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.

Zebisch A, Hatzl S, Pichler M, Wölfler A, Sill H.

Int J Mol Sci. 2016 Dec 10;17(12). pii: E2080. Review.

6.

miRNAs in acute myeloid leukemia.

Liao Q, Wang B, Li X, Jiang G.

Oncotarget. 2017 Jan 10;8(2):3666-3682. doi: 10.18632/oncotarget.12343. Review.

7.

High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia.

Fu L, Fu H, Zhou L, Xu K, Pang Y, Hu K, Wang J, Tian L, Liu Y, Wang J, Jing H, Huang W, Ke X, Shi J.

Sci Rep. 2016 Sep 30;6:34546. doi: 10.1038/srep34546.

8.

The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid Leukemia.

Shen C, Chen MT, Zhang XH, Yin XL, Ning HM, Su R, Lin HS, Song L, Wang F, Ma YN, Zhao HL, Yu J, Zhang JW.

PLoS Genet. 2016 Sep 12;12(9):e1006259. doi: 10.1371/journal.pgen.1006259. eCollection 2016 Sep.

9.

Targeting the RAS/MAPK pathway with miR-181a in acute myeloid leukemia.

Huang X, Schwind S, Santhanam R, Eisfeld AK, Chiang CL, Lankenau M, Yu B, Hoellerbauer P, Jin Y, Tarighat SS, Khalife J, Walker A, Perrotti D, Bloomfield CD, Wang H, Lee RJ, Lee LJ, Marcucci G.

Oncotarget. 2016 Sep 13;7(37):59273-59286. doi: 10.18632/oncotarget.11150.

10.

miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.

Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Gamis AS, Oehler VG, Alonzo TA, Meshinchi S.

Pediatr Blood Cancer. 2016 Dec;63(12):2096-2103. doi: 10.1002/pbc.26157. Epub 2016 Aug 11.

11.

MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses.

Shivarov V, Dolnik A, Lang KM, Krönke J, Kuchenbauer F, Paschka P, Gaidzik VI, Döhner H, Schlenk RF, Döhner K, Bullinger L.

Haematologica. 2016 Nov;101(11):e454-e456. Epub 2016 Jul 28. No abstract available.

12.

Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies.

Okuma HS, Koizumi F, Hirakawa A, Nakatochi M, Komori O, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Br J Cancer. 2016 Aug 9;115(4):411-9. doi: 10.1038/bjc.2016.184. Epub 2016 Jul 14.

13.

MicroRNAs as biomarkers in leukemia.

Wang X, Zhu B, Huang Z, Chen L, He Z, Zhang H.

Stem Cell Investig. 2014 May 27;1:11. doi: 10.3978/j.issn.2306-9759.2014.04.01. eCollection 2014. Review.

14.

Clinical significance of microRNAs in chronic and acute human leukemia.

Yeh CH, Moles R, Nicot C.

Mol Cancer. 2016 May 14;15(1):37. doi: 10.1186/s12943-016-0518-2. Review.

15.

MicroRNAs in Myeloid Hematological Malignancies.

Ciccone M, Calin GA.

Curr Genomics. 2015 Oct;16(5):336-48. doi: 10.2174/138920291605150710122815.

16.

Reduced miR-215 expression predicts poor prognosis in patients with acute myeloid leukemia.

Wang YX, Zhang TJ, Yang DQ, Yao DM, Yang L, Zhou JD, Deng ZQ, Ma JC, Guo H, Wen XM, Lin J, Qian J.

Jpn J Clin Oncol. 2016 Apr;46(4):350-6. doi: 10.1093/jjco/hyv204. Epub 2016 Jan 21.

17.

Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.

Huang H, Jiang X, Wang J, Li Y, Song CX, Chen P, Li S, Gurbuxani S, Arnovitz S, Wang Y, Weng H, Neilly MB, He C, Li Z, Chen J.

Cancer Lett. 2016 Mar 28;372(2):157-65. doi: 10.1016/j.canlet.2015.12.032. Epub 2016 Jan 11.

18.

Rare Cytogenetic Abnormalities and Alteration of microRNAs in Acute Myeloid Leukemia and Response to Therapy.

Shahjahani M, Khodadi E, Seghatoleslami M, Asl JM, Golchin N, Zaieri ZD, Saki N.

Oncol Rev. 2015 Mar 9;9(1):261. doi: 10.4081/oncol.2015.261. eCollection 2015 Feb 10. Review.

19.

miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells.

Nanbakhsh A, Visentin G, Olive D, Janji B, Mussard E, Dessen P, Meurice G, Zhang Y, Louache F, Bourhis JH, Chouaib S.

Oncoimmunology. 2015 Oct 16;4(12):e996475. eCollection 2015 Dec.

20.

MicroRNAs' Involvement in Osteoarthritis and the Prospects for Treatments.

Yu XM, Meng HY, Yuan XL, Wang Y, Guo QY, Peng J, Wang AY, Lu SB.

Evid Based Complement Alternat Med. 2015;2015:236179. doi: 10.1155/2015/236179. Epub 2015 Oct 26. Review.

Supplemental Content

Support Center